Antiinflammatory therapy with canakinumab for atherosclerotic disease Academic Article uri icon

Overview

MeSH Major

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Atherosclerosis
  • Interleukin-1beta
  • Myocardial Infarction

abstract

  • Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846 .).

authors

publication date

  • September 21, 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1707914

PubMed ID

  • 28845751

Additional Document Info

start page

  • 1119

end page

  • 1131

volume

  • 377

number

  • 12